FDA Accepts Andrx’ Corrective Action Plan On Manufacturing Issues

Agency’s acceptance means that manufacturing deficiencies will not result in warning letter or consent decree, and will not hold up ANDA approvals, Andrx CEO Rice says.

More from Archive

More from Pink Sheet